TCGA-CQ-A4CG-01A-11R-A266-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.098173516
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.480
- G2M_CHECKPOINT+0.380
- UNFOLDED_PROTEIN_RESPONSE+0.380
- E2F_TARGETS+0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.370
- PROTEIN_SECRETION+0.370
- MYC_TARGETS_V2+0.360
- HYPOXIA+0.350
- TGF_BETA_SIGNALING+0.350
- MITOTIC_SPINDLE+0.340
Top 10 suppressed
- MYOGENESIS-0.290
- ALLOGRAFT_REJECTION-0.220
- KRAS_SIGNALING_DN-0.200
- CHOLESTEROL_HOMEOSTASIS-0.120
- APICAL_SURFACE-0.110
- OXIDATIVE_PHOSPHORYLATION-0.100
- BILE_ACID_METABOLISM-0.090
- ESTROGEN_RESPONSE_EARLY-0.080
- FATTY_ACID_METABOLISM-0.080
- ESTROGEN_RESPONSE_LATE-0.060
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934963 | — | — | 0.874 |
| 2 | SRR934981 | — | — | 0.841 |
| 3 | TCGA-ZF-AA4N-01A-11R-A38B-07 | — | — | 0.824 |
| 4 | TCGA-78-7145-01A-11R-2039-07 | — | cohortA1 | 0.815 |
| 5 | BS_1D6PZNKN | Diffuse intrinsic pontine glioma | — | 0.814 |
| 6 | 726D58A7-23E0-492A-B5CE-15DCB11B0C90 | — | — | 0.808 |
| 7 | 1B940F72-3C90-43C4-9267-185F21D10AC9 | — | — | 0.807 |
| 8 | BS_F6V1Y4QS | Glial-neuronal tumor NOS | — | 0.803 |
| 9 | C3N-00211 | — | cohortSQ1 | 0.802 |
| 10 | SRR934899 | — | — | 0.799 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.480 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.380 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.370 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.370 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.360 | Idelalisib | — uncovered |
| HYPOXIA | 0.350 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.350 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.340 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.330 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.320 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.310 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.310 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.290 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.290 | Cobimetinib | — uncovered |
| GLYCOLYSIS | 0.280 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.270 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.240 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.230 | Idelalisib | — uncovered |